Mumbai: Domestic pharma retail market clocked a robust 15% growth during 2011, mainly driven by therapies like anti-diabetic, vitamin, anti-infectives and dermatology. The pharma sector continued to show its resilience amid slowdown concerns in the economy with December posting a strong growth, with anti-infectives back in favour during the month. The domestic pharma retail reached a new milestone by recording overall sales of Rs 60,000 crore for the year 2011.
The pharma market grew at 15.7% during December, with growth in key therapy areas, including anti-diabetics, derma and vitamins outperformed the market, data compiled by market research firm AIOCD (All India Organization of Chemists and Druggists) said. While the growth in anti-infectives and pain and analgesics at 11% and 12.1%, respectively, grew slower than the market during the month.
During December 2011, the companies that reported a strong year-on-year growth significantly above the pharma market include Glenmark (35.3%), Sun Pharma (27.5%), Pfizer (27.9%) and IPCA Laboratories (21.6%). While Sun has grown more consistently due to its large presence in the chronic segment, Glenmark and Ranbaxy have seen bouts of high and low growth due to larger acute dependence, experts say.
The laggards for the month include Ranbaxy (5.1%), Zydus Cadila (9.8%), Dr Reddy's (11.0%) and Cipla (13.6%), an analyst from Nomura stated.
Also, during December, Sun remains the fastest growing company in the top 10, and Macleod's clocked growth in range of 40% level.
The top pecking order in terms of market share was led by multinational Abbott (6.11%), and followed by Cipla (5.14%) and GlaxoSmithKline (4.86%) at the second and third slots during the month. Sun Pharma was ranked fourth with a 4.79% share, and Ranbaxy fifth, clocking a 4.34% market share.
No comments:
Post a Comment